Efficacy, durability and safety of faricimab for patients with neovascular age-related macular degeneration: 48-week results from the phase 3 LUCERNE China subpopulation

Zou, Wen-Jun; Jiang, Qin; Wang, Yanling; Wei, Wenbin; Sun, Xiaodong; Basu, Karen; Chen, Qiuyu; Kotecha, Aachal; N Li, S; Liu, Ruyuan; Patel, Vaibhavi; Chen, Youxin

doi:10.1016/j.apjo.2025.100142

Public

Efficacy, durability and safety of faricimab for patients with neovascular age-related macular degeneration: 48-week results from the phase 3 LUCERNE China subpopulation

Published in Asia-Pacific Journal of Ophthalmology • Jan 1, 2025

Authors:

Wen-Jun Zou

Qin Jiang

Yanling Wang

Abstract

PURPOSE: To evaluate the efficacy, durability and safety of intravitreal faricimab versus aflibercept over 48 weeks in patients with neovascular age-related macular degeneration (nAMD) from the LUCERNE China subpopulation. DESIGN: LUCERNE (NCT03823300) was a phase 3 global, double-masked, active com...

Subject

Macular degeneration

Medicine

China

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!